Therefore, simultaneous inhibition of RRM2 by CHKi in the absence of the external electron donor Trx1 renders RNR inactive to a greater extent than CHK1i treatment alone, leading to a drastic loss of the dNTP pool that further sensitizes the anti-tumor effects of the drug. The gene discussed is NR2E3; the disease is neoplasm.